Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...